The Flamma Group, a global, fully integrated company producing and commercializing small molecule Active Pharmaceutical Ingredients (APIs) for the life science industry, and CDMO of New Chemical Entities (NCEs) and late-stage intermediates, is investing $200 million over the next three years as the company continues to respond to market demand.   Flamma will invest in the following projects: • Revamping and improving the Bulciago, Italy site that was acquired in 2022. • Completion of a new G...